Solana (NASDAQ:HSDT) Downgraded by Wall Street Zen to Sell

by · The Markets Daily

Wall Street Zen cut shares of Solana (NASDAQ:HSDT – Free Report) from a hold rating to a sell rating in a research report report published on Saturday.

Several other brokerages also recently commented on HSDT. Weiss Ratings restated a “sell (e+)” rating on shares of Solana in a research note on Friday, July 17th. Zacks Research upgraded shares of Solana to a “hold” rating in a research report on Monday, April 27th. Finally, B. Riley Financial began coverage on shares of Solana in a report on Thursday, April 23rd. They set a “buy” rating and a $3.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $3.50.

Check Out Our Latest Report on Solana

Solana Price Performance

Solana stock opened at $1.70 on Friday. The business has a 50 day simple moving average of $1.67 and a 200 day simple moving average of $1.95. The company has a market capitalization of $99.26 million, a PE ratio of -0.06 and a beta of 1.01. Solana has a one year low of $1.19 and a one year high of $25.50.

Solana (NASDAQ:HSDT – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.36). Solana had a negative net margin of 1,427.15% and a negative return on equity of 67.57%. The company had revenue of $2.53 million during the quarter, compared to the consensus estimate of $3.50 million. Equities analysts anticipate that Solana will post -0.09 earnings per share for the current fiscal year.

Institutional Trading of Solana

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD bought a new position in shares of Solana in the fourth quarter valued at about $46,000. OMERS ADMINISTRATION Corp acquired a new position in Solana during the 4th quarter worth about $88,000. Aristides Capital LLC bought a new stake in Solana during the 4th quarter worth about $137,000. XTX Topco Ltd bought a new stake in Solana during the 4th quarter worth about $140,000. Finally, Saba Capital Management L.P. bought a new stake in Solana during the 1st quarter worth about $113,000. 18.63% of the stock is currently owned by institutional investors and hedge funds.

Solana News Summary

Here are the key news stories impacting Solana this week:

  • Positive Sentiment: Solana Company expects to receive its first validator-related rewards in the third quarter of 2026 after committing 500,000 SOL to support its Tokyo validator cluster. The initiative could create an additional recurring revenue stream and expand the company’s institutional presence in Asia-Pacific. Solana Company expects first validator-related rewards
  • Positive Sentiment: Second-quarter revenue rose to approximately $2.5 million from $43,000 a year earlier, primarily from staking. The company also earned 31,200 SOL in staking rewards, completed the divestiture of its legacy PoNS medical-device business, launched its first Tokyo institutional validator cluster and raised $7.9 million through a registered direct offering. Solana Company Reports Second Quarter 2026 Financial Results
  • Neutral Sentiment: The earnings call highlighted the company’s strategy of combining SOL treasury management, staking, validator infrastructure and advisory services. Execution of these initiatives may increase long-term value, but future rewards and business growth remain dependent on SOL prices, capital availability and adoption. Solana Company Q2 2026 Earnings Call Transcript
  • Negative Sentiment: Quarterly results missed expectations: adjusted loss was $0.05 per share versus the expected $0.02 loss, while revenue of $2.53 million fell short of the $3.50 million consensus estimate. Solana Company Reports Q2 Loss, Lags Revenue Estimates
  • Negative Sentiment: GAAP net loss expanded to $30.3 million, with operating expenses reaching $35.1 million, including elevated administrative and divestiture costs. The company had only $3.6 million in cash at quarter-end and an accumulated deficit of $342.6 million, increasing concerns about profitability and financing needs.
  • Negative Sentiment: Wall Street Zen downgraded HSDT to “Sell,” adding to the negative reaction to the earnings miss and continued losses. Wall Street Zen Downgrades Solana to Sell

About Solana

(Get Free Report)

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.

Featured Stories